- Home
- DCTH vs PROK Comparison
DCTH vs PROK Comparison
Compare DCTH & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCTH | PROK |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.7M | 331.2M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DCTH | PROK |
|---|---|---|
| Price | $8.89 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $22.00 | $7.40 |
| AVG Volume (30 Days) | 347.4K | ★ 704.0K |
| Earning Date | 05-07-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $33.15 | $25.00 |
| P/E Ratio | $128.14 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $8.12 | $0.46 |
| 52 Week High | $18.23 | $7.13 |
Technical Indicators
Market Signals| Indicator | DCTH | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 28.91 |
| Support Level | $8.49 | $0.54 |
| Resistance Level | $10.17 | $2.58 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 6.06 | 5.76 |
Price Performance
Historical ComparisonAbout DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.